Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

J.N. Fiessinger; H. Bounameaux; M.A. Cairols; D.L. Clement; S. Coccheri; J.P. Fletcher; U. Hoffmann; A.G.G. Turpie; R.I. Baker

doi:10.1111/j.1538-7836.2010.04020.x

Back

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

Journal article

Peer reviewed

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

J.N. Fiessinger, H. Bounameaux, M.A. Cairols, D.L. Clement, S. Coccheri, J.P. Fletcher, U. Hoffmann, A.G.G. Turpie and R.I. Baker

Journal of Thrombosis and Haemostasis, Vol.8(11), pp.2369-2376

2010

DOI: https://doi.org/10.1111/j.1538-7836.2010.04020.x

Files and links (1)

url

Free to Read *No subscription requiredView

Abstract

BACKGROUND: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic, antivasoconstrictive and antiatherosclerotic properties and is currently in development for long-term cardiovascular secondary prevention. OBJECTIVES: TAIPAD is an international, double-blind, randomized controlled study comparing the effects of five dosages of oral terutroban vs. aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients. PATIENTS/METHODS: After 10 day's placebo run-in, included patients (n = 435; ankle-brachial pressure index, 0.7 ± 0.1) were randomly allocated to aspirin 75 mg day(-1), terutroban 1, 2.5, 5, 10 or 30 mg day(-1) or placebo. On day 5, the placebo group was reallocated to one of the terutroban groups for the rest of the study (day 83). Ex vivo platelet aggregation induced by the thromboxane analog U46619 (7 μm) was measured 24 h after dosing, as well as platelet aggregation induced by arachidonic acid (AA), collagen and ADP. RESULTS: Terutroban dose-dependently inhibited U46619-induced platelet aggregation at days 5 and 83. At day 5, the inhibition was significant vs. placebo for all terutroban dosages (P < 0.001). Terutroban (5, 10 and 30 mg day(-1)) was at least as effective as aspirin in inhibiting platelet aggregation induced by arachidonic acid (AA), collagen and adenosine diphosphate (ADP). Terutroban was well tolerated, with a safety profile similar to aspirin. CONCLUSIONS: In PAD patients, terutroban dose-dependently inhibited platelet aggregation 24 h after dosing, and was at least as effective as aspirin at 5, 10 and 30 mg day(-1). Terutroban was well tolerated.

Details

Title: Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study
Authors/Creators: J.N. Fiessinger (Author/Creator)
H. Bounameaux (Author/Creator)
M.A. Cairols (Author/Creator)
D.L. Clement (Author/Creator)
S. Coccheri (Author/Creator)
J.P. Fletcher (Author/Creator)
U. Hoffmann (Author/Creator)
A.G.G. Turpie (Author/Creator)
R.I. Baker (Author/Creator)
Publication Details: Journal of Thrombosis and Haemostasis, Vol.8(11), pp.2369-2376
Publisher: Wiley-Blackwell
Identifiers: 991005545149707891
Copyright: © 1999 - 2017 John Wiley & Sons, Inc.
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Language: English
Resource Type: Journal article
Additional Information: Murdoch University authors made contribution to this work as part of the TAIPAD Study

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

35 Record Views

26 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.71 Cardiology - Circulation; 1.71.193 Acute Myocardial Infarction
Web Of Science research areas: Hematology; Peripheral Vascular Disease
ESI research areas: Clinical Medicine